Limited Asian Fallout From Pfizer-Allergan Merger?
This article was originally published in Scrip
As far as Asian and emerging pharma markets go, it is clear that Pfizer Inc. will be the dominant partner in the planned $160bn merger with Allergan PLC. The US firm has a broad reach in these areas that Allergan will be looking to tap into, and major restructuring in big regional markets such as China and Japan looks unlikely.
You may also be interested in...
Despite so many COVID-19 uncertainties, e.l.f. Beauty has the confidence of a company that posted 6% net sales growth to $283m for the 2020 fiscal year ended on 31 March and is seeing its value proposition for "prestige-quality" cosmetics resonate even more powerfully with consumers in today’s volatile economic climate.
Latest warning to Humaworm notes findings that FDA inspectors made in July 2019. FDA officials apparently have been in Humaworm’s facility since then, executing a search warrant in October and confiscating encapsulating machines, herbs, capsules, computers, and records.
After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted by the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.